Leung, Jacky K. http://orcid.org/0000-0002-7530-9382
Imamura, Yusuke
Kato, Minoru
Wang, Jun
Mawji, Nasrin R.
Sadar, Marianne D. http://orcid.org/0000-0003-0599-9215
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA105304)
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre
Scholarships to JKL from Canadian Institutes of Health Research and the University of British Columbia.
Article History
Received: 6 April 2020
Accepted: 1 March 2021
First Online: 22 March 2021
Competing interests
: The authors declare the following competing interests: J.K.L, Y.I., M.K., J.W., N.M., and M.D.S. are inventors of technology pertaining to AR NTD inhibitors, which was licensed by the BC Cancer Agency to ESSA Pharma Inc. M.D.S. owns equity in and is a Scientific Advisor for ESSA Pharma. Their interests were reviewed and are managed by the BC Cancer Agency in accordance with its research conflict of interest policy.